Nxera Pharma Co., Ltd. (4565.T)
JPY 1056.0
(1.15%)
JPY 1056.0
(1.15%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 73.97 Billion JPY | 148.78% |
| 2022 | 29.73 Billion JPY | 1.58% |
| 2021 | 29.27 Billion JPY | 76.09% |
| 2020 | 16.62 Billion JPY | 784.67% |
| 2019 | 1.87 Billion JPY | -73.02% |
| 2018 | 6.96 Billion JPY | -24.08% |
| 2017 | 9.17 Billion JPY | 32.94% |
| 2016 | 6.9 Billion JPY | -21.92% |
| 2015 | 8.83 Billion JPY | -55.54% |
| 2014 | 19.87 Billion JPY | 0.0% |
| 2013 | - JPY | 0.0% |
| 2012 | - JPY | 0.0% |
| 2011 | - JPY | 0.0% |
| 2010 | - JPY | 0.0% |
| 2009 | - JPY | 0.0% |
| 2008 | - JPY | 0.0% |
| 2007 | - JPY | 0.0% |
| 2006 | - JPY | 0.0% |
| 2005 | - JPY | 0.0% |
| 2004 | - JPY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 65.75 Billion JPY | -7.48% |
| 2024 Q2 | 71.07 Billion JPY | -1.93% |
| 2024 Q1 | 72.47 Billion JPY | -2.03% |
| 2023 Q3 | 73.3 Billion JPY | 140.75% |
| 2023 Q4 | 73.97 Billion JPY | 0.91% |
| 2023 FY | 73.97 Billion JPY | 148.78% |
| 2023 Q2 | 30.45 Billion JPY | 1.91% |
| 2023 Q1 | 29.87 Billion JPY | 0.49% |
| 2022 FY | 29.73 Billion JPY | 1.58% |
| 2022 Q4 | 29.73 Billion JPY | 0.22% |
| 2022 Q1 | 29.51 Billion JPY | 0.82% |
| 2022 Q2 | 29.65 Billion JPY | 0.48% |
| 2022 Q3 | 29.66 Billion JPY | 0.05% |
| 2021 FY | 29.27 Billion JPY | 76.09% |
| 2021 Q1 | 16.79 Billion JPY | 1.0% |
| 2021 Q2 | 16.82 Billion JPY | 0.18% |
| 2021 Q3 | 29.12 Billion JPY | 73.17% |
| 2021 Q4 | 29.27 Billion JPY | 0.49% |
| 2020 Q2 | 1.65 Billion JPY | -3.11% |
| 2020 Q1 | 1.7 Billion JPY | -9.26% |
| 2020 Q4 | 16.62 Billion JPY | 0.42% |
| 2020 FY | 16.62 Billion JPY | 784.67% |
| 2020 Q3 | 16.55 Billion JPY | 902.06% |
| 2019 Q3 | 6.38 Billion JPY | -11.03% |
| 2019 FY | 1.87 Billion JPY | -73.02% |
| 2019 Q2 | 7.17 Billion JPY | -10.56% |
| 2019 Q1 | 8.01 Billion JPY | 0.0% |
| 2019 Q4 | 1.87 Billion JPY | -70.55% |
| 2018 Q1 | 9.17 Billion JPY | -7.38% |
| 2018 Q3 | 7.75 Billion JPY | -8.15% |
| 2018 Q2 | 8.43 Billion JPY | -8.01% |
| 2018 FY | 6.96 Billion JPY | -24.08% |
| 2017 Q1 | 6.9 Billion JPY | -6.58% |
| 2017 FY | 9.17 Billion JPY | 32.94% |
| 2017 Q4 | 9.9 Billion JPY | -6.87% |
| 2017 Q3 | 10.63 Billion JPY | -6.03% |
| 2017 Q2 | 11.31 Billion JPY | 64.01% |
| 2016 FY | 6.9 Billion JPY | -21.92% |
| 2016 Q4 | 7.38 Billion JPY | -6.15% |
| 2016 Q1 | 8.83 Billion JPY | -5.17% |
| 2016 Q3 | 7.87 Billion JPY | -5.79% |
| 2016 Q2 | 8.35 Billion JPY | -5.47% |
| 2015 Q2 | 19.93 Billion JPY | 0.3% |
| 2015 FY | 8.83 Billion JPY | -55.54% |
| 2015 Q3 | 9.79 Billion JPY | -50.85% |
| 2015 Q4 | 9.31 Billion JPY | -4.9% |
| 2015 Q1 | 19.87 Billion JPY | 132417.19% |
| 2014 Q4 | 15 Million JPY | 0.0% |
| 2014 Q3 | - JPY | 0.0% |
| 2014 Q2 | - JPY | 0.0% |
| 2014 Q1 | - JPY | 0.0% |
| 2014 FY | 19.87 Billion JPY | 0.0% |
| 2013 FY | - JPY | 0.0% |
| 2013 Q1 | - JPY | 0.0% |
| 2013 Q2 | - JPY | 0.0% |
| 2013 Q4 | - JPY | 0.0% |
| 2013 Q3 | - JPY | 0.0% |
| 2012 Q3 | - JPY | 0.0% |
| 2012 Q1 | - JPY | 0.0% |
| 2012 FY | - JPY | 0.0% |
| 2012 Q4 | - JPY | 0.0% |
| 2012 Q2 | - JPY | 0.0% |
| 2011 FY | - JPY | 0.0% |
| 2011 Q4 | - JPY | 0.0% |
| 2011 Q1 | - JPY | 0.0% |
| 2011 Q3 | - JPY | 0.0% |
| 2011 Q2 | - JPY | 0.0% |
| 2010 FY | - JPY | 0.0% |
| 2010 Q2 | - JPY | 0.0% |
| 2010 Q3 | - JPY | 0.0% |
| 2010 Q1 | - JPY | 0.0% |
| 2010 Q4 | - JPY | 0.0% |
| 2009 Q3 | - JPY | 0.0% |
| 2009 Q4 | - JPY | 0.0% |
| 2009 FY | - JPY | 0.0% |
| 2009 Q1 | - JPY | 0.0% |
| 2008 Q4 | - JPY | 0.0% |
| 2008 FY | - JPY | 0.0% |
| 2007 FY | - JPY | 0.0% |
| 2006 FY | - JPY | 0.0% |
| 2005 FY | - JPY | 0.0% |
| 2004 FY | - JPY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 2.46 Billion JPY | -2895.228% |
| PRISM BioLab Co.,LTD | - JPY | -Infinity% |
| GNI Group Ltd. | 3.69 Billion JPY | -1899.576% |
| Linical Co., Ltd. | 3 Billion JPY | -2364.204% |
| Trans Genic Inc. | 2.25 Billion JPY | -3177.405% |
| MEDINET Co., Ltd. | 2.3 Million JPY | -3206358.604% |
| Soiken Holdings Inc. | - JPY | -Infinity% |
| Cytori Cell Research Institute, Inc. | 2.47 Billion JPY | -2892.721% |
| AnGes, Inc. | 362.67 Million JPY | -20296.498% |
| OncoTherapy Science, Inc. | 106.84 Million JPY | -69131.345% |
| Immuno-Biological Laboratories Co., Ltd. | 235.98 Million JPY | -31246.882% |
| NanoCarrier Co., Ltd. | 1.1 Billion JPY | -6570.749% |
| Carna Biosciences, Inc. | 182.97 Million JPY | -40328.811% |
| CanBas Co., Ltd. | - JPY | -Infinity% |
| D. Western Therapeutics Institute, Inc. | 885.12 Million JPY | -8257.379% |
| RaQualia Pharma Inc. | 367.71 Million JPY | -20016.774% |
| Chiome Bioscience Inc. | 291 Million JPY | -25320.275% |
| Kidswell Bio Corporation | 2.57 Billion JPY | -2772.738% |
| PeptiDream Inc. | 22.79 Billion JPY | -224.445% |
| Oncolys BioPharma Inc. | 315.17 Million JPY | -23370.825% |
| Ribomic Inc. | - JPY | -Infinity% |
| SanBio Company Limited | 665 Million JPY | -11023.759% |
| Healios K.K. | 4.53 Billion JPY | -1532.237% |
| BrightPath Biotherapeutics Co., Ltd. | 112.5 Million JPY | -65653.778% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 142.85 Million JPY | -51682.602% |
| Delta-Fly Pharma, Inc. | - JPY | -Infinity% |
| StemRIM | - JPY | -Infinity% |
| CellSource Co., Ltd. | 97.54 Million JPY | -75737.075% |
| FunPep Company Limited | - JPY | -Infinity% |
| Kringle Pharma, Inc. | - JPY | -Infinity% |
| Stella Pharma Corporation | 933.3 Million JPY | -7825.962% |
| TMS Co., Ltd. | - JPY | -Infinity% |
| Noile-Immune Biotech Inc. | - JPY | -Infinity% |
| Cuorips Inc. | - JPY | -Infinity% |
| K Pharma,Inc. | - JPY | -Infinity% |
| Takara Bio Inc. | 968 Million JPY | -7541.839% |
| ReproCELL Incorporated | - JPY | -Infinity% |
| PhoenixBio Co., Ltd. | 723.93 Million JPY | -10118.239% |
| StemCell Institute Inc. | 8.78 Million JPY | -842033.424% |
| Japan Tissue Engineering Co., Ltd. | - JPY | -Infinity% |
| CellSeed Inc. | 151.25 Million JPY | -48807.769% |